It was stated that the drug ‘PF-07321332’ developed by Pfizer for coronavirus could be available towards the end of the year after trials.
“We designed PF-07321332 as a potential oral treatment that can be applied at the first sign of infection without requiring patients to be hospitalized or remain in intensive care,” said Mikael Dolsten, head of Pfizer’s worldwide research, development, and medical division, who announced the start of manned trials of a drug that covid-19 patients can use orally in March.
A month-long manned trial of the drug also involved volunteers aged between 18 and 60.
Dr. Penny Ward, of King’s College London, said: “If they have progressed to this stage they will be very optimistic.”
Pfizer explained that the first phase of trials was designed to look at ‘significant side effects and how people feel after taking the drug’, in addition to the drug’s performance.
The second stage will examine how participants responded to multiple doses, while the third will focus on the effect of eating while on the drug.
Further trials will be required to determine how the drug works in people infected with the coronavirus.
If the results of the trials are promising, the drug could be available later this year.